Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from "assessment of Pexelizumab in Acute Myocardial Infarction" Academic Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Electrocardiography
  • Heart Failure
  • Myocardial Infarction
  • Outcome Assessment (Health Care)
  • Shock, Cardiogenic
  • Single-Chain Antibodies

abstract

  • Survival after CS remains poor despite aggressive reperfusion. Both CS and CHF remain the major causes of death among STEMI patients undergoing primary PCI. Future studies should examine treatments that aim to reduce mortality in these highest risk patients.

publication date

  • July 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2011.04.009

PubMed ID

  • 21742094

Additional Document Info

start page

  • 89

end page

  • 97

volume

  • 162

number

  • 1